3rd Real-World Evidence World Congress 2025 Europe
Hilton London Kensington, London, UK
Day 2 - Wednesday 30th April 2025
CHALLENGES AND POTENTIALS
- Challenges that could inhibit the administration and efficiency of RWE
- Best practices and lessons learned from other industries
- Collaboration between regulators and RWD/RWE organisations to develop collective experience so that RWE use can be better regulated
- Analyzing RWD to determine brand marketing effectiveness
- Major factors contributing to the pharmaceutical industry’s excitement about RWE
- Addressing the challenges of collecting and consolidating RWD data that can be put to good use.
- Important role of RWE clinical trials
- Real-world data and evidence as a more integral part of the drug development process.
- How are patient registries used to generate real-world data for rare diseases and orphan drugs?
- Does different stakeholder types have different RWE information needs for decision making?
- Well-targeted evidence which encourages orphan medicine adoption by supporting the approval, reimbursement, and prescribing
- Benefits of understanding differences across stakeholders
- Multiple stakeholder approach to planning and delivering evidence is required
- A dedicated strategy to meet their specific evidence needs
- Determine whether a multiple stakeholder approach is justified.
- The shift from RCT to RWE; closing the gap
- Best practices and lessons learned in developing robust RWE studies
- Using Real-World Evidence to accelerate market access
- Example of technologies currently being used to harness data
- Are there pitfalls in using these technologies?
- How are these new technologies providing valuable understanding of the use of RWE in real-world settings
- Upcoming development
- Collection of high-quality patient-centered data relevant to the design, conduct, and translation of real- world research.
- Applying qualitative patient experience data to make informed study design decisions
- Recommendations that may improve the patient centricity of RWE
- Why personalised medicines require RWE and disruptive technologies intervention?
- Data that have potential to be implemented in personalized medicines discovery
- How will RWE curve the future path of personalized, precision medicines
- Glimpse into a future of next-generation medicine
- Recent advances in scientific research and technologies
- Main areas that need improvement
- Innovative strategies needed to engage patients and generate the necessary evidence to propel new advances into the clinic
- Latest changes in RWE landscape and its advantages
- What exciting new breakthroughs exist for RWE?
- The next big innovations and advances in RWE
- Perspective on future directions and harmonisation